[Federal Register Volume 81, Number 112 (Friday, June 10, 2016)]
[Notices]
[Pages 37603-37604]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13787]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-D-1264]
Dissemination of Patient-Specific Information From Devices by
Device Manufacturers; Draft Guidance for Industry and Food and Drug
Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the draft guidance entitled ``Dissemination of
Patient-Specific Information from Devices by Device Manufacturers.''
The FDA developed this draft guidance to facilitate the appropriate and
responsible dissemination of patient-specific information recorded,
stored, processed, retrieved, and/or derived from medical devices from
manufacturers to patients. This draft guidance provides recommendations
to industry, healthcare providers, and FDA staff about the mechanisms
and considerations for device manufacturers sharing such information
with patients. This draft guidance is not final nor is it in effect at
this time.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment of this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by August 9, 2016.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to http://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on http://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
[[Page 37604]]
Instructions: All submissions received must include the Docket No.
FDA-2016-D-1264 for ``Dissemination of Patient-Specific Information
from Devices by Device Manufacturers.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at http://www.regulations.gov or at
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on http://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the draft guidance document entitled
``Dissemination of Patient-Specific Information from Devices by Device
Manufacturers'' to the Office of the Center Director, Guidance and
Policy Development, Center for Devices and Radiological Health, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431,
Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to
assist that office in processing your request.
FOR FURTHER INFORMATION CONTACT: Sugato De, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 5435, Silver Spring, MD 20993-0002, 301-796-6270,
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Increasingly, patients seek to play an active role in their own
healthcare. FDA believes that manufacturers providing patients with
accurate, useable information about their healthcare (including the
medical products they use and patient-specific information these
products generate) will improve healthcare by empowering patients to
participate fully with their healthcare providers in making sound
medical decisions. For purposes of this guidance, patient-specific
information is defined as any information unique to an individual
patient or unique to that patient's treatment or diagnosis that may be
recorded, stored, processed, retrieved, and/or derived from a medical
device. This information may include, but is not limited to, recorded
patient data, device usage/output statistics, healthcare provider
inputs, incidence of alarms, and/or records of device malfunctions or
failures.
FDA developed this draft guidance to convey FDA's policy regarding
the dissemination of patient-specific information recorded, stored,
processed, retrieved, and/or derived from a medical device and provided
by the manufacturer to the patient who is either treated or diagnosed
with that specific device. This draft guidance document also outlines
considerations for the form in which this information is communicated
to help to ensure clarity of content and appropriate context.
Manufacturers may share patient-specific information (recorded,
stored, processed, retrieved, and/or derived from a medical device,
consistent with the intended use of that medical device) with patients
either on their own initiative or at the patient's request, without
obtaining additional premarket review before doing so. Any labeling, as
that term is defined in section 201(m) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act), that is provided to the patient by the
manufacturer is subject to applicable requirements in the FD&C Act and
FDA regulations.
II. Significance of Guidance
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance when
finalized will represent the current thinking of FDA on ``Dissemination
of Patient-Specific Information from Devices by Device Manufacturers.''
It does not establish any rights for any person and is not binding on
FDA or the public. You can use an alternative approach if it satisfies
the requirements of the applicable statutes and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by downloading an electronic copy from the Internet. A search
capability for all Center for Devices and Radiological Health guidance
documents is available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at http://www.regulations.gov. Persons
unable to download an electronic copy of ``Dissemination of Patient-
Specific Information from Devices by Device Manufacturers'' may send an
email request to [email protected] to receive an electronic
copy of the document. Please use the document number 1500067 to
identify the guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations and guidance. These collections of
information are subject to review by the Office of Management and
Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-
3520). The collections of information in 21 CFR parts 801 and 809,
regarding device labeling, are approved under OMB control number 0910-
0485.
Dated: June 6, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-13787 Filed 6-9-16; 8:45 am]
BILLING CODE 4164-01-P